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Solid phase microextraction coupled to mass spectrometry via 
microfluidic interface for rapid therapeutic drug monitoring  
Nikita T Loobya, Marcos Tascona,١, Vinicius R Acquaro Jra,b,٢, Nathaly Reyes-Garcésa,٢ , Tijana 
Vasiljevica, German Augusto Gomez-Riosa,٢ , Marcin Wąsowicz c*, Janusz Pawliszyna*
Tranexamic acid (TXA) is an antifibrinolytic used during cardiac surgery that presents high inter-patient 
variability. High plasma concentrations have been associated with post-operative seizures. Due to the 
difficulties with maintaining acceptable concentrations of TXA during surgery, implementation of a point-of-
care strategy for testing TXA plasma concentration would allow for close monitoring of its concentration during 
administration. This would facilitate timely corrections to the dosing schedule, and in effect tailor treatment 
for individual patient needs. In this work, a method for the rapid monitoring of TXA from plasma samples was 
subsequently carried out via biocompatible solid-phase microextraction (Bio-SPME) coupled directly to 
tandem mass spectrometry via a microfluidic open interface (MOI). MOI operates under the concept of a flow-
isolated desorption volume and was designed with aims to directly hyphenate Bio-SPME to different detection 
and ionization systems. In addition, it allows the desorption of Bio-SPME fibers in small volumes while it 
concurrently continues feeding the ESI with a constant flow to minimize cross-talking and instabilities. The 
methodology was used to monitor six patients with varying degrees of renal dysfunction, at different time 
points during cardiac surgery. MOI proves to be a reliable and feasible tool for rapid therapeutic drug 
monitoring. Affording total times of analysis as low as 30 seconds per sample in its high throughput mode 
configuration while the single sample turn-around time was 15 minutes, including sample preparation. In 
addition, cross-validation against a standard thin film solid phase microextraction using liquid chromatography 
coupled to tandem mass spectrometry (TFME-LC-MS/MS) method was performed. Bland-Altman analysis was 
used to cross-validate the results obtained by the two methods. Data analysis demonstrated that 92 % of the 
compared data pairs (n = 63) were distributed within the acceptable range. The data was also validated by the 
Passing Bablok regression, demonstrating good statistical agreement between these two methods. Finally, the 
currently presented method offers comparable results to the conventional liquid chromatography with 
acceptable RSDs, while only necessitating a fraction of the time. In this way, TXA concentration in plasma can 
be monitored in a close to real time throughput during surgery.   
Introduction
Tranexamic acid (TXA), classified as an antifibrinolytic agent, is a 
synthetic lysine analogue that works by inhibiting plasminogen and 
thus prevents its conversion to plasmin, an enzyme that degrades 
fibrin in blood clots.1. This medication is used to stop or reduce 
bleeding in a wide variety of haemorrhagic conditions.2 For instance, 
it is used in a number of high-risk operations such as cardiac surgery, 
liver transplantation, as well as in emergency rooms to treat cases of 
haemorrhaging as a result of trauma.1,2 Its safety profile provides 
significant advantages over older generation antifibrinolytic agents 
such as aprotinin and ecallantide, which have been linked to 
increased mortality, increased post-operative bleeding, increased 
blood transfusion requirements, and kidney failure.2 Although no 
major risk factors have been reported in relation to the use of TXA in 
clinical applications, increased incidences of post-operative seizures 
in cardiac surgical patients have been reported in association with its 
increased clinical use in high doses.1,2  A number of investigations 
directed at reaching the appropriate target concentrations unveiled 
high inter-patient variability for TXA, in that therapeutic levels varied 
greatly from patient to patient, often exceeding the target 
concentrations of both high dose and low dose dosing schedules.2,3 
Recently, Jerath et al. carried out a study demonstrating that 
exceedingly high TXA plasma levels – beyond 100 µg/mL – may be 
attributed to poor drug clearance from the system as a result of 
kidney dysfunction or failure.4 The above investigation was carried 
out by measuring levels of TXA in the plasma of patients presenting 
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varying stages of kidney damage who were undergoing cardiac 
surgery with the use of TXA.5 These findings aided in the 
development of a new dosing regimen that accommodates patients 
who suffer from renal insufficiency. In this context, the development 
of technologies geared at fast and precise point-of-care (POC) 
analysis play a vital role in further advances in personalized 
medicine.6 Such developments are especially critical in cases where 
the inter-patient variability is high, necessitating accurate regulation 
of dosage to produce the desired therapeutic effect. 
 In this context, the direct coupling of solid-phase microextraction 
(SPME) to ambient mass spectrometry (MS) has emerged as a 
solution that efficiently integrates the sample preparation step with 
analysis.7–9 Indeed, several clinical applications reported to date have 
demonstrated the ability of this platform to both minimize overall 
time of analysis as well as mass spectrometer contamination.10–13 In 
this work, a novel recently developed MOI that directly couples SPME 
to tandem mass spectrometry (MS/MS) in order to measure TXA is 
presented.14 This interface allows for efficient analyte transmission 
into the electrospray ionization (ESI) interface; hence, allowing a 
dramatic reduction in acquisition time when compared to the 
traditional liquid chromatography (LC) protocol (time scale on order 
of seconds by MOI versus time scale on order of minutes by LC).15 
Furthermore, after extraction, analytes collected onto the SPME 
devices are eluted for a period of 5 seconds into an open microfluidic 
desorption chamber which subsequently rapidly introduces the plug 
of desorbed analytes into the ESI interface and allows for improved 
sensitivity in comparison to other SPME-MS approaches.16 In light of 
the recently reported connection between TXA use and post-
operative seizures, and considering the well-documented sizable 
inter-patient variability of this drug, the currently presented 
technology was applied for the high-throughput monitoring of TXA 
in plasma samples taken from patients presenting different stages of 
renal damage undergoing cardiac surgery. Assessments carried out 
at various time-points, from five minutes after the bolus was 
injected, up until 72 hours post-surgery. The technology was also 
cross-validated against a previously validated thin film solid phase 
microextraction (TFME) with the use of LC-MS/MS method.17 The 
methodology showed turnaround times of 15 minutes per sample for 
single-injection analysis (i.e. one sample at the time), and less than 
30 seconds per sample for high-throughput analysis (i.e. extraction 
from a 96-well plate). These results demonstrate the capabilities of 
this technique towards close to real-time analysis of TXA, while 
evidencing its great potential for therapeutic drug monitoring in a 
wide range of clinical applications. 
Experimental methods and materials
Chemicals and materials
Tranexamic acid (trans-4-(aminomethyl)cyclohexanecarboxylic acid), 
the internal standard cis-4-aminocyclohexanecarboxylic acid, LC-MS 
grade formic acid, HPLC grade acetonitrile and methanol as well as 
chemicals used to prepare phosphate buffered saline (PBS), namely 
sodium chloride, potassium chloride, potassium phosphate 
monobasic, sodium phosphate dibasic were purchased from Sigma-
Aldrich (Oakville, ON, Canada). Deionized water was obtained from a 
Milli-Q Reference A+ water purification system (Fisher Scientific). LC-
MS grade water, used to prepare PBS as well as the stock solutions, 
was purchased from Fisher Scientific (Ottawa, ON, Canada). Human 
plasma (sodium citrate) was obtained from Lampire Biological 
Laboratories Inc. (Pipersville, PA, USA). HLB SupelTM-Select particles 
(~ 60 µm) used for thin-film solid phase microextraction (TFME) were 
kindly provided by Supelco (Bellefonte, PA, USA), while HLB particles 
(~ 5 µm) used to fashion Bio-SPME fibres were kindly provided by 
Waters Corporation (Winslow, UK). Polypropylene 96-well 2 mL deep 
plates were purchased from Fisher Scientific (ON, Canada).
Human plasma samples
All procedures employed in this study, including the retrieval of 
samples from patients, were approved by the Research Ethics Boards 
of the Toronto General Hospital/ University Health Network and the 
University of Waterloo. Each patient signed an informed consent 
while recruited to participate in the study. Plasma samples were 
obtained from patients undergoing elective high or low risk cardiac 
surgery under cardiopulmonary bypass (CPB). For high risk (HR) 
cardiac surgery the dose administered was as outlined in the Blood 
Conservation Using Antifibrinolytics in a Randomized Trial (BART) 
study18 whereby 30 mg/kg bolus of TXA infused over a 15 min span 
post induction of anaesthesia (period 1) followed by an infusion of 
TXA at a dose of 16 mg/kg·hr (period 2) until the sternotomy was 
closed with a 2 mg/kg load in the pump prime. For low risk (LR) 
cardiac surgery, the dose was as per institutional practise at Toronto 
General Hospital as outlined by Jerath et al5 whereby patients 
received a bolus dose of 50 mg/kg post induction of anaesthesia. The 
sampling protocol, which is schematically demonstrated in 
supplementary information S1 – figure S1, was as outlined in 
previous research.17 Blood samples were first collected at baseline 
and then  at 5 min and 10 min during period 1  which was the 
administration of a bolus dose (single dose of TXA given to the 
patient by injection into a blood vessel). During period 2, whereby 
TXA was infused, samples were collected post sternotomy (chest 
opening), immediately before and after the start of CPB, and at 30 
min intervals during CPB for up to four sampling points. Samples 
were collected again after CPB and prior to chest closing. Finally, in 
period 3 - the post operation (postop) period - samples were 
collected at 1 hr, 2 hr, 4 hr, 8 hr, 12 hr, 24 hr, 48 hr, and 72 hr. A total, 
114 samples were expected to be collected from 6 patients, with 
each of the 19 samples obtained, processed in triplicate. However, 
only 86 samples were obtained from 6 patients undergoing cardiac 
surgery for reasons undisclosed. 
High throughput analysis with concept-96 unit
The concept-96, shown in supplementary information S2 – figure S2, 
is a software-operated system that automatically performs each step 
of the SPME protocol: pre-conditioning, extraction, rinsing, and 
desorption.19 It houses a robotic arm, where either the 96 blades or 
fibres can be immobilized. These devices are compatible with 96-well 
plates, which can be stationed in their respective compartments on 
the unit. The system allows for preparation of up to 96 samples at 
once. After completing the sample preparation workflow, well plates 
can be deposited directly into the auto sampler of the LC system. 
Sample preparation
All samples, including human plasma samples used to create the 
matrix-matched external calibration curve, were prepared as 
follows: 250 µL of sample was placed in a 2 mL well, and diluted with 
750 µl of a PBS solution containing the internal standard. The dilution 
of samples (1:3) was supported for this application due to the high 
therapeutic levels of TXA in the samples, as well as negligible binding 
of TXA to plasma proteins (~ 3%).20 Extractions from the prepared 
samples were carried out with TFME in brush format and Bio-SPME 
fibres; both compatible with the 96-well plate format. Please see 
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supplementary information S3 for more information on preparation 
of standards and calibration curve.
Instrumental analysis:
SPME-LC-MS/MS
The TFME brush was prepared using a spray protocol developed in-
house.21 The device was coated with 60 µm HLB particles, and 
characterized by final coating dimensions of 2 cm length and 0.3 mm 
thickness.22 Collected patient samples were prepared for analysis in 
96-well plates, which were then mounted on their respective 
stations on the Concept-96. The SPME protocol for the LC-MS/MS 
method was as follows: pre-conditioning of the coating was carried 
out in 1.5 mL 50:50 (v/v) methanol/water for 15 min at 1500 rpm; 
extraction was performed at room temperature (25 ⁰C) from 1 mL of 
biological matrix for 5 min at 1500 rpm; a 10 s agitated rinse (1500 
rpm) was carried out in 1 mL 90:10 (v/v) water/methanol; and 
desorption was completed in 1 mL 3:3:4 (v/v/v) 
acetonitrile/methanol/water for 10 min at 1500 rpm. The desorption 
plate was then mounted into the autosampler and 10 µL of resultant 
extracts were withdrawn for LC-MS/MS analysis. Chromatography 
and mass spectrometry details can be found in supplementary 
information S4 and table S1. Chromatograms of the typical signals for 
blank plasma and patient samples are shown in supplementary 
information S4 – figures S3 and S4 respectively. 
BIO-SPME-MOI-MS/MS
Bio-SPME fibres were prepared on a nitinol support in accordance to 
a dipping method developed in our laboratory.12 The final 
dimensions of the fibres were 4 mm coating length and 20 µm of 
thickness, using 5 µm HLB particles.  Parameters for analysis via MOI-
MS/MS were as follows: extraction time was 15 min, followed by two 
5 s rinsing steps with water, then desorption for 5 seconds at the MOI 
device, which was directly coupled to the mass spectrometer API 
4000 triple quadrupole (AB SCIEX, Concord, Ontario). The 
operational duty cycle and performance of this interface is described 
in detail elsewhere.14,15,23 The LC pump employed for fluid delivery 
was a 200 Series Perkin Elmer (Santa Clara, CA, USA), while ionization 
was produced with the use of a TurboIonTM spray source. Conditions 
required for the desorption step consisted of an equilibrium between 
the pump flow at (350 μL·min-1) and the electrospray ionization (ESI) 
aspiration. Essentially, the MOI device is designed with two 
sections14 as shown  in the second step of the analytical workflow in 
figure 1. The top section, which functions as the SPME desorption 
chamber, consists of a Teflon cylinder with two holes connected by a 
channel of a smaller diameter.14 The connection between the open 
ambient desorption chamber and the electrospray needle employed 
in this device was inspired by the design of the open-port interface 
reported by Van Berkel et al.9,13–15,23 Succinctly, the procedure 
involves the employment of two co-axial tubes that allow for solvent 
delivery through the gap formed between these two tubes. Once the 
solvent reaches the top of the coaxial tubes, it is aspirated towards 
the MS by means of the Venturi effect produced by the ESI source. 
ESI parameters were as follows: positive ion mode; nitrogen gas set 
at GS1 = 90, GS2 = 70; collision gas (CAD) = 6; curtain gas = 25; heated 
nebulizer temperature = 300 °C; and electrospray voltage = 5000 V. 
More information can be found in the supplementary information S5 
and table S2. Chromatograms of the typical signals for blank plasma 
and patient samples are shown in supplementary information S5 – 
figures S5 and S6 respectively. The solvent employed in the MOI-
MS/MS system was methanol with 0.1% v/v formic acid. These 
conditions provided better sensitivity for this direct-to-MS 
application than acetonitrile or the desorption conditions used for 
TFME-LC-MS/MS. 
Results and discussion
SPME-MOI as a tool for rapid analysis of clinical samples
Given that tranexamic acid is known to present high inter-patient 
variability, concentration levels for TXA should be closely monitored 
in patients over the course of treatment. In this regard, previous 
studies have demonstrated the emergence of a two-group stratified 
Figure 1: Analytical workflow for Bio-SPME-MOI-MS/MS
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trend of TXA plasma concentration for patients receiving the same 
therapeutic treatment.2 For the confirmatory high throughput study 
performed by Jerath et al,5 patients were first categorized based on 
the type of cardiac surgery endured – low risk (LR) or high risk (HR). 
Within each group, patients were further categorised by healthy 
renal function and on the basis of degree of chronic renal 
dysfunction, stages 1 – 5; stage 1 being normal or increased 
glomerular filtration rate (GFR) and stage 5 being kidney failure.5 As 
the use of TF-SPME technology for monitoring TXA in plasma has 
already been validated in previous research17,20,24 against traditional 
methods such as ultrafiltration (UF) and plasma protein precipitation 
(PPP) which is routinely used for analysis in clinical applications, the 
same technology, with a few modifications was employed for this 
high throughput study. Given that all patients within the same risk  
category (high risk or low risk) were submitted to the same dosing 
schedule, the drastic differences observed in patient profiles as seen 
in figure 2 (for example high risk patients in figure 2D, 2E and 2F, 
patients with more severe chronic renal dysfunction (CRD) 
experience elevated and persistently high TXA concentrations – 
figure 2D and 2E – in comparison to patients with normal kidney 
function – figure 2F) endorses not only the need for revision and 
adjustment of the current TXA dosing schedule for cardiac surgical 
patients, but also the necessity of rapid sample analysis technology 
to facilitate POC testing. The former would generally contribute 
towards improving the recovery of patients post operation, 
particularly those with renal impairment, while the latter would 
better navigate clinical practitioners in personalizing treatment peri-
operatively. Herein, we explain how Bio-SPME-MOI-MS/MS can be 
used as an alternative technology for rapid high throughput analyses 
of clinically relevant samples containing TXA. For instance, Figure 1 
shows two sample preparation workflows that can be used with this 
technology. The first approach, the single injection strategy, allows 
for turnaround times under 15 minutes. The second approach, 
namely the high throughput workflow, as illustrated in Figure 1, 
allows for simultaneous extraction of TXA from up to 96 plasma 
samples. Hence, total sample preparation time drops to less than 10 
seconds per sample, with total analysis times of approximately 30 
seconds per sample given that the operator needs to manually place 
each Bio-SPME device on the MOI. As such, this method not only 
offers the selectivity provided by mass spectrometry and the efficient 
sample clean-up afforded by SPME but also facilitates rapid sample 
throughput due to semi-automation via the Concept-96. The Bio-
SPME-MOI-MS/MS method produced a coefficient of determination 
(R2) of 0.997 and a linear dynamic range over more than two orders 
of magnitude (refer to figure 1), from 25µg/mL – 1000 µg/mL, 
comparable to the TFME-LC-MS/MS method. However, an LOQ of 25 
µg/mL was obtained for the MOI-MS/MS as opposed to the LOQ of 5 
µg/mL obtained for LC-MS/MS. These differences reflect the 
differences observed in recoveries for the target compound, which 
were dependent on the geometry utilized for analysis, whereby a 1% 
recovery was experienced for the TFME method in comparison to a 
0.1 % recovery for the Bio-SPME method. Nonetheless, the range of 
concentrations that are expected to be encountered during TXA 
administration are well above these LOQs, with the target 
therapeutic level estimated to be 100 µg/mL. The method was 
validated in human plasma at a working concentration of 100 µg/mL, 
with an inter-day precision of 20 %, a corresponding average 
accuracy of 91 % (n = 15), and an intra-day precision of 20 %, 
corresponding to an average accuracy of 95 % (n = 5) (See 
supplementary information S6 – figure S7).
Figure 2: Patient profiles of 6 patients from two different risk groups. Figures 2A, 2B and 2C show profiles for patients who underwent low risk cardiac 
surgery with Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) dosing schedule. Figures 2D, 2E and 2F show profiles of patients 
who underwent high risk cardiac surgery with a dosing schedule as per institutional practise at the Toronto General Hospital. Results obtained via 
SPME-LC-MS/MS is represented by bars in dark blue while results obtained via SPME-MOI-MS/MS are represented by grey bars.
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As a result, figure 2 shows the relatively close reproducibility of 
patient profiles by Bio-SPME-MOI-MS/MS in comparison to the trend 
generated by TFME-LC-MS/MS from both sets of patients undergoing 
high-risk (HR) or low-risk (LR) cardiac surgical procedures. Each bar 
plot shows the comparison of MOI (represented by grey bars) vs LC 
(represented by dark blue bars) for the concentration of tranexamic 
acid in plasma at each time point over the course of surgery. The 
profiles generated by Bio-SPME-MOI-MS/MS are very similar to 
profiles obtained by TFME-LC-MS/MS in that the same trend for a 
particular individual was observed. For instance, HR-Patient 24 had 
much higher TXA levels between CPB-30 (30 minutes after the start 
of cardiopulmonary bypass) and post-op-4hour (4 hours post 
operation after removal of CPB and cessation of TXA IV infusion) 
compared to the concentrations prior to Pre-CPB (start of surgery 
before cardiopulmonary bypass was implemented). In other patients 
however, such as HR-Patient 20 and HR-Patient 21, although TXA 
concentrations remain high (greater than 100 µg/mL), there is a 
more obvious decreasing trend of TXA plasma concentrations over 
the course of surgery, unlike that seen with HR-Patient 24. All three 
patients of this risk group belong to stage 4 chronic renal 
dysfunction. Despite belonging to the same stage and receiving the 
same dosing schedule, there are clear differences in the profiles 
between these patients. LR-Patient 26 and LR-Patient 28 experienced 
a sharp drop in concentration around CPB-30, however the 
concentration levels essentially plateaued at these lower 
concentrations with a slight spike at pre-closure and postop 1 hour 
from LR-Patient 26 until concentrations finally decreased during the 
post op period around 12 hours and 24 hours for LR-Patient 26 and 
LR-Patient 28 respectively. However, LR-Patient 6 experienced a 
much sharper decreasing trend than the other patient counterparts 
in the same risk group and especially in comparison to those patients 
in the high-risk group. The concentration plateau seen in LR-Patient 
26 and LR-Patient 28 are indicative of increased residence time of 
TXA in plasma due to poor renal filtration as both patients belong to 
stage 4 renal dysfunction whereas LR-Patient 6 belongs to stage 2 
renal dysfunction. These results comparing MOI-MS/MS to LC-
MS/MS are astounding, especially considering the large difference in 
time of analysis that exists between the two methods. For instance, 
approximately 19 continuous hours would be needed to process 96 
samples via LC-MS/MS as opposed to the less than 2 hours needed 
for the manually operated MOI-MS/MS workflow to produce 
comparable results. Moreover, the proposed method proves 
robustness, as the samples were run on a blinded basis and 
completely randomized.
Statistical validation of the MOI methodology 
Figure 3 and Figure 4 demonstrate the results of the statistical 
validation performed on the data acquired from both methods. The 
Passing-Bablok regression, shown in Figure 3, was constructed in 
order to statistically cross-validate the SPME-MOI-MS/MS method 
for monitoring TXA in plasma with the previously validated SPME-LC-
MS/MS method. The Passing-Bablok regression uses an orthogonal 
regression algorithm which assumes that measurement imprecision 
is present in both methods under comparison. Six patients, were 
analysed initially by SPME-LC-MS/MS for the purposes of the high 
throughput study.4 Both methods exhibited consistency in signal 
response over concentration. From the 86 sample pairs that were 
obtained from measurements with LC vs MOI from 6 patients, 25 
pairs exhibited statistically different results (p < 0.05) and were 
therefore excluded from further analysis. As such, n = 63 pairs were 
used for further statistical cross validation of the two methods. The 
results from the regression, which included 63 sampling pairs suggest 
equal suitability for both methods, with a slope of 0.984 (0.909 to 
1.06), and an intercept of 11.049 (1.91 to 16.3). A statistical 
comparison of the two methods via the Spearman correlation 
coefficient yielded a value of 0.958 (0.931 to 0.974), further 
indicating that the methods have a linear relationship and are highly 
correlated (p < 0.01). Furthermore, to supplement the results of the 
Passing-Bablok regression, a Bland-Altman plot was constructed. The 
Bland-Altman plot shown in Figure 4 shows that the mean absolute 
difference in TXA quantification was observed to be 9.0. A value of 
±1.96 standard deviation (SD) was used for the limit of agreement 
values (LOA), thus obtaining an interval from −39.6 (lower agreement 
limit) to 57.6 (upper agreement limit). The number of data pairs 
observed to be beyond the LOA value was 5 out of 63, which 
confirmed a Bland–Altman index of 7.9%. Thus, 92.1 % of the 
compared pairs were distributed within the acceptable range (within 
the ±1.96 SD limit). The comparative results presented low 
discrepancy between both methods, with the majority of the values 
distributed around the mean (9.0) and completely random, 
indicating that no tendency is present in the analysis. Thus, 
confirming the suitability of Bio-SPME-MOI-MS/MS for the 
monitoring of TXA in plasma samples.
Figure 3: Passing-Bablok regression from data from LC-MS/MS vs 
MOI-MS/MS Figure 4: Bland-Altman plot of data pairs (n=63) of LC-MS/MS and MOI-MS/MS. 
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MS-based POC technologies
The MOI has already demonstrated to have about one order of 
magnitude more sensitivity than the open port probe interface for 
Bio-SPME applications for several targeted compounds.9,14 The main 
differences were attributed to the small desorption volume 
employed as well as the static desorption allowing for a very sharp 
injection plug. Additionally, this technology is complementary to 
other ambient technologies such as DART and DESI which have been 
implemented in a number of clinical applications and are largely 
employed in a wide range of bioanalytical applications including 
screening of small molecules in biological fluids, 2D imaging of tissues 
and high throughput screening and drug discovery, respectively.25–28 
However, most of these applications are directed towards the 
analysis of compounds present in high concentrations where strong 
matrix effects are not compromising the detectability. When sample 
preparation for direct-to-MS approaches is taken into account, the 
most widespread is SPE.29,30 RapidfireTM especially, has been 
demonstrated to be useful for therapeutic drug monitoring of 
immunosuppressive drugs in whole blood with sample turnaround 
times of less than 15 s.30 However, for total analysis time, the number 
of steps is not fully contemplated including protein precipitation, 
incubation and centrifugation. Noteworthy, Unlike SPME, in SPE this 
protocol cannot be skipped in clinical samples such as whole blood 
or plasma due to the chances of cartridge clogging. Regarding SPME-
MS interfaces, Coated blade spray (CBS)7 is another concept, that has 
also shown potential for high throughput therapeutic drug 
monitoring affording sample analysis times of less than 55 s.11 As a 
substrate spray method, the entire blade can be exposed to a fluid 
sample for a predetermined amount of time, thereby conducting an 
SPME based extraction.10,11 Alternatively, similar to Paper spray (PS), 
a spot analysis can be performed wherein a small sample volume can 
be directly applied to the blade coating surface prior to desorption/ 
ionization. There are fewer methodologies still, like PS, that are used 
for quantitative therapeutic drug monitoring and POC analysis.31,32   
Given that SPME fibers can be easily interfaced with the MOI, this 
technology offers a unique advantage not only as an alternative 
approach to the bulk of these strategies but also a complementary 
technique as it can be used for both quantitative in vivo and ex vivo 
analysis.9,13,14,16 Owing to the SPME device’s small diameter (Ø < 250 
µm), MOI presents a breakthrough for rapid quantitative and 
qualitative practices for assessing more complex biological materials 
such as various tissues/organs that have been subjected to therapy.
Conclusions
The work herein presented demonstrates that employment of liquid 
chromatography instrumentation for quantitation of TXA in plasma 
can be circumvented by directly coupling SPME to mass 
spectrometry via the developed MOI, thereby dramatically 
improving sample throughput. In fact, to the best of our knowledge, 
it is the first time that a SPME-MS approach is validated for a large 
number of clinical samples demonstrating the feasibility for rapid 
therapeutic drug monitoring. Since SPME integrates sample 
preparation and sample clean-up in one step, while being amenable 
for automation with the 96-concept, a large number of plasma 
samples from patients can be prepared and subsequently submitted 
to instrumental analysis within a short period of time, affording total 
analysis time of less than 30 seconds per sample. The currently 
presented method achieved a linear dynamic range between 25 
µg/mL – 1000 µg/mL, which is comparable to that produced by 
TFME-LC-MS/MS. This LOQ of 25 µg/mL result is suitable for the 
range of TXA concentrations expected from such clinical applications; 
and undoubtedly reproduced the profiles of 6 patients from two 
different risk groups, with an average accuracy and precision of 95% 
and 20 %, respectively. It must also be noted that despite Bio-SPME-
MOI-MS/MS did not achieve similar precision as found by TFME-LC-
MS/MS method, the attained values are nonetheless sufficient and 
acceptable for a POC or screening methodology. Presumably, one of 
the main contributing factors behind the observed difference in 
performance may be attributed to the absence of an autosampler for 
conducting the analysis since the fibers were introduced manually to 
the MOI. Uncertainties in the final quantitative data may arise 
because of variations in the reaction times of placing or removing the 
fibers into or from the MOI, as well as variations in the amount of 
time that elapsed for desorption and switching the flow to allow 
aspiration. Additionally, the fibers used were prepared in laboratory 
using a relatively novel dipping strategy developed in house.12 The 
use of commercially available fibers can be a source of potential 
improvement. Furthermore, although use of an internal standard is 
meant to correct for any possible variations, the internal standard 
used was not an isotopically labelled standard which may not 
completely address the system variations. Nevertheless, the Passing-
Bablok regression was performed to cross-validate the developed 
MOI methodology against the LC-MS/MS gold standard. The 
correlation was slightly lower in the lower concentration range 
(intercept) due to the differences in LOQ achieved by LC-MS/MS vs 
MOI-MS/MS respectively. However, the assays agreed reasonably 
well in the expected TXA concentration range for both methods 
(slope of the regression line 0.931 to 0.974). Bio-SPME-MOI offers a 
breakthrough for rapid sample analysis and high sample throughput 
 requirements for on-site clinical applications such as therapeutic 
drug monitoring and POC testing. With the necessity for rapid sample 
analysis afoot, based on the work presented herein and the 
possibility of mass spectrometers being introduced into clinical 
settings, this technology can be implemented for real-time analysis 
of biological samples in hospitals and clinics, providing and easy to 
use tool for POC-testing, screening, and onsite therapeutic drug 
monitoring in biofluids and/or tissues either in vivo or ex vivo. 
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